-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 21, 2021, Eli Lilly and Company announced that it is the third critical phase 3 of the investigational IL-13 inhibitor lebrikizumab combined with topical corticosteroids (TCS) for the treatment of patients with moderate to severe atopic dermatitis The clinical trial, which reached all its primary and key secondary endpoints at week 16, proved that the lebrikizumab combination therapy group can significantly improve the severity of the patient’s disease
Atopic dermatitis, also known as eczema, is a chronic inflammatory skin disease caused by skin barrier dysfunction and immune response disorders
Lebrikizumab is an innovative monoclonal antibody drug that can bind IL-13 with high affinity and specificity, thereby preventing the formation of IL-13Rα1/IL-4Rα complex and inhibiting the receptor complex-mediated Signal pathway
This randomized, double-blind, placebo-controlled phase 3 study aims to evaluate the efficacy and safety of lebrikizumab combined with TCS in the treatment of adults and adolescents (age 12 to less than 18 years old, weighing at least 40 kg) with moderate to severe atopic dermatitis
The primary endpoint of the trial is the 16th week.
Reference materials:
[1] Lilly's lebrikizumab demonstrated significant skin improvement and itch relief when combined with topical corticosteroids in people with atopic dermatitis in third Phase 3 study.
[2] Moyle et al.
(The original text has been deleted)
